The use of artificial intelligence in drug discovery is becoming increasingly common at Big Pharma and little biotech alike. We’ll talk to several leaders in the AI field to learn about some examples of their work. Can they speed the development of more drugs with better odds of success? The answer may well divide the winners and losers in the future.
Putting AI in R&DC T2023-02-12T05:22:37-05:00
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.